Immunocore Holdings plc (NASDAQ:IMCR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have earned a consensus rating of “Moderate Buy” from the thirteen analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $81.00.

A number of brokerages recently commented on IMCR. Barclays decreased their target price on Immunocore from $92.00 to $66.00 and set an “overweight” rating for the company in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Wednesday, June 5th. Needham & Company LLC reissued a “buy” rating and issued a $81.00 price target on shares of Immunocore in a research report on Friday. Mizuho decreased their price target on shares of Immunocore from $90.00 to $88.00 and set a “buy” rating for the company in a research note on Monday, May 13th. Finally, SVB Leerink started coverage on shares of Immunocore in a research note on Monday, April 29th. They issued an “outperform” rating and a $74.00 price objective on the stock.

Immunocore Stock Performance

NASDAQ:IMCR opened at $37.63 on Thursday. The company has a quick ratio of 5.94, a current ratio of 5.96 and a debt-to-equity ratio of 1.22. Immunocore has a twelve month low of $33.04 and a twelve month high of $76.98. The company has a fifty day moving average of $38.33 and a 200-day moving average of $53.50. The firm has a market capitalization of $1.88 billion, a P/E ratio of -30.84 and a beta of 0.75.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.25. Immunocore had a negative net margin of 22.60% and a negative return on equity of 16.54%. The firm had revenue of $75.40 million during the quarter, compared to the consensus estimate of $74.58 million. During the same period in the previous year, the firm posted ($0.37) earnings per share. The business’s revenue was up 26.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Immunocore will post -1.98 EPS for the current year.

Institutional Investors Weigh In On Immunocore

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMCR. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Immunocore by 28.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,152 shares of the company’s stock valued at $1,104,000 after acquiring an additional 3,623 shares in the last quarter. Mutual of America Capital Management LLC purchased a new stake in shares of Immunocore during the 4th quarter valued at $940,000. HealthInvest Partners AB purchased a new stake in shares of Immunocore during the 4th quarter valued at $534,000. New York State Common Retirement Fund raised its stake in shares of Immunocore by 23.1% during the 4th quarter. New York State Common Retirement Fund now owns 244,439 shares of the company’s stock worth $16,700,000 after purchasing an additional 45,798 shares during the period. Finally, Jump Financial LLC boosted its holdings in shares of Immunocore by 57.2% in the 4th quarter. Jump Financial LLC now owns 44,900 shares of the company’s stock worth $3,068,000 after buying an additional 16,345 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.